These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 25977345)

  • 1. Pharmacologic Inhibition of JAK1/JAK2 Signaling Reduces Experimental Murine Acute GVHD While Preserving GVT Effects.
    Carniti C; Gimondi S; Vendramin A; Recordati C; Confalonieri D; Bermema A; Corradini P; Mariotti J
    Clin Cancer Res; 2015 Aug; 21(16):3740-9. PubMed ID: 25977345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect.
    Choi J; Cooper ML; Alahmari B; Ritchey J; Collins L; Holt M; DiPersio JF
    PLoS One; 2014; 9(10):e109799. PubMed ID: 25289677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IFNγR signaling mediates alloreactive T-cell trafficking and GVHD.
    Choi J; Ziga ED; Ritchey J; Collins L; Prior JL; Cooper ML; Piwnica-Worms D; DiPersio JF
    Blood; 2012 Nov; 120(19):4093-103. PubMed ID: 22972985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody-drug conjugates plus Janus kinase inhibitors enable MHC-mismatched allogeneic hematopoietic stem cell transplantation.
    Persaud SP; Ritchey JK; Kim S; Lim S; Ruminski PG; Cooper ML; Rettig MP; Choi J; DiPersio JF
    J Clin Invest; 2021 Dec; 131(24):. PubMed ID: 34730109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel JAK Inhibitors to Reduce Graft-Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation in a Preclinical Mouse Model.
    Kim S; Ruminski P; Singh M; Staser K; Ashami K; Ritchey J; Lim S; DiPersio JF; Choi J
    Molecules; 2024 Apr; 29(8):. PubMed ID: 38675621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ruxolitinib, a JAK1/JAK2 selective inhibitor, ameliorates acute and chronic steroid-refractory GvHD mouse models.
    Huarte E; Peel M; Juvekar A; Dubé P; Sarah S; Stephens L; Stewart B; Long B; Czerniak P; Oliver J; Smith P
    Immunotherapy; 2021 Aug; 13(12):977-987. PubMed ID: 34184542
    [No Abstract]   [Full Text] [Related]  

  • 7. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease.
    Spoerl S; Mathew NR; Bscheider M; Schmitt-Graeff A; Chen S; Mueller T; Verbeek M; Fischer J; Otten V; Schmickl M; Maas-Bauer K; Finke J; Peschel C; Duyster J; Poeck H; Zeiser R; von Bubnoff N
    Blood; 2014 Jun; 123(24):3832-42. PubMed ID: 24711661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical evaluation of JAK1/2 inhibition by ruxolitinib in a murine model of chronic graft-versus-host disease.
    Ryu DB; Lim JY; Kim TW; Shin S; Lee SE; Park G; Min CK
    Exp Hematol; 2021 Jun; 98():36-46.e2. PubMed ID: 33811972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic Effects of a NEDD8-Activating Enzyme Inhibitor, Pevonedistat, on Sclerodermatous Graft-versus-Host Disease in Mice.
    Pai CS; Khuat LT; Chen M; Murphy WJ; Abedi M
    Biol Blood Marrow Transplant; 2017 Jan; 23(1):30-37. PubMed ID: 27815049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of JAK1/2 inhibition on bone marrow stromal cells of myeloproliferative neoplasm (MPN) patients and healthy individuals.
    Zacharaki D; Ghazanfari R; Li H; Lim HC; Scheding S
    Eur J Haematol; 2018 Jul; 101(1):57-67. PubMed ID: 29645296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutrophils provide cellular communication between ileum and mesenteric lymph nodes at graft-versus-host disease onset.
    Hülsdünker J; Ottmüller KJ; Neeff HP; Koyama M; Gao Z; Thomas OS; Follo M; Al-Ahmad A; Prinz G; Duquesne S; Dierbach H; Kirschnek S; Lämmermann T; Blaser MJ; Fife BT; Blazar BR; Beilhack A; Hill GR; Häcker G; Zeiser R
    Blood; 2018 Apr; 131(16):1858-1869. PubMed ID: 29463561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant IL-7/HGFβ hybrid cytokine separates acute graft-versus-host-disease from graft-versus-tumour activity by altering donor T cell trafficking.
    Hu R; Liu Y; Song Y; Su M; Lu X; Rood D; Lai L
    Br J Haematol; 2016 Nov; 175(3):505-516. PubMed ID: 27447780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with a rho kinase inhibitor improves survival from graft-versus-host disease in mice after MHC-haploidentical hematopoietic cell transplantation.
    Iyengar S; Zhan C; Lu J; Korngold R; Schwartz DH
    Biol Blood Marrow Transplant; 2014 Aug; 20(8):1104-11. PubMed ID: 24796280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ruxolitinib for the treatment of graft-versus-host disease.
    Ali H; Salhotra A; Modi B; Nakamura R
    Expert Rev Clin Immunol; 2020 Apr; 16(4):347-359. PubMed ID: 32153201
    [No Abstract]   [Full Text] [Related]  

  • 16. NKG2D expression by CD8+ T cells contributes to GVHD and GVT effects in a murine model of allogeneic HSCT.
    Karimi MA; Bryson JL; Richman LP; Fesnak AD; Leichner TM; Satake A; Vonderheide RH; Raulet DH; Reshef R; Kambayashi T
    Blood; 2015 Jun; 125(23):3655-63. PubMed ID: 25788701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ruxolitinib treatment for steroid refractory acute and chronic graft vs host disease in children: Clinical and immunological results.
    González Vicent M; Molina B; González de Pablo J; Castillo A; Díaz MÁ
    Am J Hematol; 2019 Mar; 94(3):319-326. PubMed ID: 30536806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-6 modulates graft-versus-host responses after experimental allogeneic bone marrow transplantation.
    Tawara I; Koyama M; Liu C; Toubai T; Thomas D; Evers R; Chockley P; Nieves E; Sun Y; Lowler KP; Malter C; Nishimoto N; Hill GR; Reddy P
    Clin Cancer Res; 2011 Jan; 17(1):77-88. PubMed ID: 21047980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting JAK2 reduces GVHD and xenograft rejection through regulation of T cell differentiation.
    Betts BC; Bastian D; Iamsawat S; Nguyen H; Heinrichs JL; Wu Y; Daenthanasanmak A; Veerapathran A; O'Mahony A; Walton K; Reff J; Horna P; Sagatys EM; Lee MC; Singer J; Chang YJ; Liu C; Pidala J; Anasetti C; Yu XZ
    Proc Natl Acad Sci U S A; 2018 Feb; 115(7):1582-1587. PubMed ID: 29382747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intestinal helminths regulate lethal acute graft-versus-host disease and preserve the graft-versus-tumor effect in mice.
    Li Y; Chen HL; Bannick N; Henry M; Holm AN; Metwali A; Urban JF; Rothman PB; Weiner GJ; Blazar BR; Elliott DE; Ince MN
    J Immunol; 2015 Feb; 194(3):1011-20. PubMed ID: 25527786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.